- Cancer Type
- Biopsy Type
- Results Expected
What is FoundationACT?
FoundationACT is a blood-based circulating tumor DNA (ctDNA) assay for solid tumors that identifies clinically relevant genomic alterations driving the growth of a patient's cancer. This liquid biopsy can help physicians identify treatment options by providing clinically actionable information relevant to diagnosis, risk-stratification, and prognosis. Test results provide information about potential targeted therapies and/or available clinical trials to better inform treatment decisions.
FoundationACT is validated to detect all classes of genomic alterations in more than 60 of the most commonly mutated genes in solid tumors using only a blood sample.
- A single assay that detects all 4 classes of genomic alterations required to comprehensively profile a tumor.
- Identification of resistance mutations or fusions in lung cancer, often missed by other ctDNA assays2
- Can be integrated with FoundationOne results to give a more complete picture of the evolution of a patient’s tumor
- Requires only two 10mL tubes of blood